Wall Street Journal changes position on FDA reviewer
Executive Summary
CDER Oncology Division Medical Review Officer Steven Hirschfeld, MD/PhD, praised in front page Wall Street Journal article Dec. 11 for his role in the approval of Sanofi-Synthelabo's anticancer treatment Eloxatin (oxaliplatin). The newspaper condemned the FDA oncologist a month earlier on its editorial page, calling Hirschfeld a "budding Albert Schweitzer" who disregards the welfare of cancer patients (1"The Pink Sheet" Oct. 27, p. 7)...